Adults who are overweight or obese and currently using semaglutide (Ozempic®/Wegovy®) or tirzepatide (Mounjaro®/Zepbound®) may qualify for a research study evaluating an investigational weight loss medication.
Obesity Study
Age Range:
18
Gender:
Male and Female
Location:
Rochester, New York
About the Study
This research study is evaluating maridebart cafraglutide, an investigational medication designed to help maintain weight loss in adults who have previously responded to GLP-1 treatment. The study medication is given as an injection using a prefilled syringe.
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of switching from a currently prescribed GLP-1 medication to the investigational study medication.
Participants who qualify will:
- Receive active study medication (there is no placebo group in this study)
- Continue their current GLP-1 medication until transitioning to the study medication at the randomization visit
- Participate in the study for up to approximately 83 weeks
- Attend approximately 20 study visits
- Complete electronic dosing diaries and study assessments
- Have physical exams, fasting lab work, and other safety evaluations completed throughout the study
- Be monitored for changes in weight, health, and treatment response over time
Qualifications
Qualifications
You may be able to join if you:
- Are 18 years of age or older
- Have a BMI greater than 25 kg/m²
- Have used semaglutide or tirzepatide consistently for at least 6 months
- Have maintained a stable dose of your medication for at least 6 months
- Have lost at least 10% of your body weight while using semaglutide or tirzepatide
- Have had stable body weight over the past 6 months
- Are willing to provide medical records confirming treatment history and weight loss
- Are willing and able to attend study visits and follow study procedures
FEATURED STUDIES
Adults 18 years and older may qualify for a study evaluating investigational treatment options for diabetic peripheral neuropathic pain (DPNP), […]
Adults 18 years and older may qualify for a study evaluating an investigational oral study medication for elevated lipoprotein(a) [Lp(a)], […]
Adults living with obesity or overweight who do not have type 2 diabetes may qualify for a research study evaluating […]
Adults living with obesity or overweight who do not have type 2 diabetes may qualify for a research study evaluating […]
Adults who are overweight or obese and currently using semaglutide (Ozempic®/Wegovy®) or tirzepatide (Mounjaro®/Zepbound®) may qualify for a research study […]
Adults 18 and older with obstructive sleep apnea (OSA) and overweight or obesity may qualify for a clinical study evaluating […]